|LETTER TO THE EDITOR
|Year : 2019 | Volume
| Issue : 4 | Page : 228-229
Gulucatime versus glucantime: A serious warning on counterfeit medicines
Bahareh Abtahi-Naeini1, Zabihollah Shahmoradi2, Elmira Niknami3, Ali Saffaei4
1 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
3 Student Research Committee, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
4 Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
|Date of Submission||21-Jul-2019|
|Date of Acceptance||23-Jul-2019|
|Date of Web Publication||27-Dec-2019|
Dr. Ali Saffaei
Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Abtahi-Naeini B, Shahmoradi Z, Niknami E, Saffaei A. Gulucatime versus glucantime: A serious warning on counterfeit medicines. J Res Pharm Pract 2019;8:228-9
|How to cite this URL:|
Abtahi-Naeini B, Shahmoradi Z, Niknami E, Saffaei A. Gulucatime versus glucantime: A serious warning on counterfeit medicines. J Res Pharm Pract [serial online] 2019 [cited 2020 Apr 1];8:228-9. Available from: http://www.jrpp.net/text.asp?2019/8/4/228/274161
Cutaneous leishmaniasis is caused by a flagellated parasite and transmitted through a bite by bloodsucking sand-flies. Cutaneous leishmaniasis is characterized by ulcerative skin lesions. This is an endemic disease in the Middle East, especially Iran, Afghanistan, Pakistan, Bangladesh, Indian, and Nepal. Since the 1940s, pentavalent antimony compounds have been considered as the first line of treatment for all forms of leishmaniasis. Meglumine antimoniate and sodium stibogluconate are the well-known pentavalent antimony agents. Glucantime (Sanofi Aventis, France) is a brand product of meglumine antimoniate, which is supplied in 5 mL colorless ampules with concentration 300 mg/mL. Every five ampules are packed in a box, and there are not any visible particles in Glucantime ampules. In January 2019, a batch of meglumine antimoniate under brand “Gulucatime” is imported to Iran and is distributed between certain health centers. The appearance of this product was the same as pervious “Glucantime” bathes, except the obvious typographical error [Figure 1]. Visible sediment particles in some ampules and improper packaging also were remarkable [Figure 2]. Iranian dermatologists prescribed “Gulucatime” for cutaneous leishmaniasis patients in the mentioned period. However, the clinical outcome was not seen at all, and the clinical situation of patients deteriorated. After a while, the physician suspected of the originality of the “Gulucatime” and similar reports was seen in Pakistan. Finally, the WHO Region of the Eastern Mediterranean confirmed counterfeit meglumine antimoniate (Gulucatime) circulating in Iran and Pakistan. Counterfeit drugs, especially lifesaving drugs, target the health of patients in less developed countries. It is necessary to make stronger state licensure supervision to avoid such disasters. This letter emphasis to aware the physicians regarding counterfeit meglumine antimoniate. The physician should avoid prescribing such medicines if there is any abnormal sign in medicine package, including typographical errors and sediment particles.
|Figure 2: Low-quality packaging (a) and visible sediment particles (b) in “Gulucatime” ampules|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Steverding D. The history of leishmaniasis. Parasit Vectors 2017;10:82.
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al.
Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.
Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 2015;16:237-52.
Blackstone EA, Fuhr JP Jr., Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits 2014;7:216-24.
[Figure 1], [Figure 2]